KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Cash: 2015-2025

Historic Change in Cash for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $1.3 billion.

  • BeOne Medicines' Change in Cash rose 1286.91% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 480.20%. This contributed to the annual value of -$547.2 million for FY2024, which is 20.58% up from last year.
  • Per BeOne Medicines' latest filing, its Change in Cash stood at $1.3 billion for Q3 2025, which was up 418.39% from $255.5 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Change in Cash ranged from a high of $3.4 billion in Q4 2021 and a low of -$397.0 million during Q3 2021.
  • In the last 3 years, BeOne Medicines' Change in Cash had a median value of -$108.2 million in 2025 and averaged $21.4 million.
  • As far as peak fluctuations go, BeOne Medicines' Change in Cash soared by 4,344.29% in 2021, and later crashed by 1,064.93% in 2023.
  • Quarterly analysis of 5 years shows BeOne Medicines' Change in Cash stood at $3.4 billion in 2021, then slumped by 109.62% to -$325.5 million in 2022, then surged by 132.29% to $105.1 million in 2023, then plummeted by 171.06% to -$74.7 million in 2024, then spiked by 1,286.91% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $255.5 million for Q2 2025, and -$108.2 million during Q1 2025.